Annual General Meeting of BioGaia
The Annual General Meeting of BioGaia AB on 22 April 2009 voted unanimously to approve the following resolutions:
- a dividend of SEK 0.40 per share
- re-election of Board members Jan Annwall, Stefan Elving, Thomas Flinck, David Dangoor, Inger Holmström, Jörgen Thorball and Paula Zeilon
- re-election of David Dangoor as Board Chairman
- payment of board fees in an amount of SEK 200,000 to the Chairman and SEK 100,000 to each of the other Board members not employed by the company
- regarding principles for remuneration and other terms of employment for senior executives in accordance with the Board's proposal
- regarding the Nominating Committee in accordance with Nominating Committee's proposal
- regarding amendments to the Articles of Association in accordance with the Board's proposal
All decisions that were passed by the Annual General Meeting are consistent with the Board's and Nominating Committee's previously published proposals.
Latest press releases from BioGaia:
2009-04-22 Interim report 1 January - 31 March 2009
2009-03-18 Notice to attend the Annual General Meeting of BioGaia AB
2009-03-11 BioGaia signs distribution agreement for Serbia and Croatia
For additional information contact:
Peter Rothschild, Managing Director, telephone: +46 8 -555 293 00
Jan Annwall, Deputy Managing Director, telephone: +46 8-555 293 00
BioGaia is a biotechnology company that develops, markets and sells probiotic products
with documented health benefits. The products are primarily based on the lactic acid
bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects.
The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list
of the NASDAQ OMX Nordic Exchange Stockholm.
www.biogaia.com